| Filed On | Filing |
|---|---|
| 14 Aug 2026 |
8-K/A: Results of Operations and Financial Condition
– Expanded ABI-6250 clinical development into cholestatic liver diseases, including primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) – |
| 14 Jun 2017 |
8-K/A: Submission of Matters to a Vote of Security Holders
The following proposals were submitted to the stockholders at the 2017 Annual Meeting of Stockholders (the “Annual Meeting”) of Assembly Biosciences, Inc. (the “Company”) held on June 1, 2017: |
| 17 Sep 2014 |
8-K/A: Financial Statements and Exhibits
The accompanying unaudited pro forma condensed combined financial statements reflect the combined financial position of Assembly Biosciences, Inc. (“ASMB”) and Assembly Pharmaceuticals, Inc. (“Assembly”) as of June 30, 2014, and the resu... |
| 21 Mar 2011 |
8-K/A: Financial Statements and Exhibits
* Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by refer... |
Loading...